Tirzepatide Inj recall — Class II (D-0395-2026) · pharmaranks
Class IIOngoing
Tirzepatide Inj recall
FDA recall D-0395-2026 · initiated Feb 26, 2026
May cause temporary or medically reversible harm; low probability of serious harm.
Why it was recalled
Lack of Assurance of Sterility
Details
Product
Tirzepatide Inj, 15mg x 4, Sterile Multi-Dose Vial, Rx only, Nomida, 25055 W Valley Pkwy, Suite 106, Olathe, KS 66061, NDC 84223-002-04.
Recalling company
New Life Pharma LLC
Classification
Class II
Status
Ongoing
Type
Voluntary: Firm initiated
Distribution
OH
Initiated
Feb 26, 2026
FDA report date
Mar 11, 2026
What to do.If you have a recalled product, don't throw away questions — check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This page reproduces public FDA data and is not medical advice.